Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We report that a novel AMPK catalytic subunit family member, ARK5, plays a key role in tumor malignancy downstream of Akt.
|
15060171 |
2004 |
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We identified ARK5 (AMPK-Related Protein Kinase 5, also referred to as NUAK Family Kinase 1) as a novel metabolic target present in all species, and independent analyses confirmed glucose metabolism as the most significantly aberrant cellular signaling pathway in a model system for highly metastatic tumors.
|
29100308 |
2017 |
Primary Malignant Liver Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that NUAK1 was increased in the tumor of primary liver cancer.
|
30807203 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that NUAK1 was increased in the tumor of primary liver cancer.
|
30807203 |
2019 |
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We find that WZ4003 and HTH-01-015 impaired the invasive potential of U2OS cells in a 3D cell invasion assay to the same extent as NUAK1 knockdown.
|
24171924 |
2014 |
ovarian neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Thus, activation of the ARK5/miR-1181/HOXA10 axis may be positively associated with EMT in ovarian cancer.
|
26151663 |
2015 |
Malignant neoplasm of ovary
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Thus, activation of the ARK5/miR-1181/HOXA10 axis may be positively associated with EMT in ovarian cancer.
|
26151663 |
2015 |
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Thus, activation of the ARK5/miR-1181/HOXA10 axis may be positively associated with EMT in ovarian cancer.
|
26151663 |
2015 |
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, NUAK1 inhibition may be an effective strategy for precision treatment of PTEN-deficient breast tumors.
|
29566768 |
2018 |
Malignant transformation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that c-Maf might cause a type of T-cell lymphoma in both mice and humans and that ARK5, in addition to cyclin D2 and integrin beta(7), might be downstream target genes of c-Maf leading to malignant transformation.
|
16424013 |
2006 |
T-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that c-Maf might cause a type of T-cell lymphoma in both mice and humans and that ARK5, in addition to cyclin D2 and integrin beta(7), might be downstream target genes of c-Maf leading to malignant transformation.
|
16424013 |
2006 |
Intrahepatic Cholangiocarcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that miR-145 can prevent ICC progression by targeting NUAK1 and its downstream effectors, and can therefore be useful for clinical diagnosis and targeted therapy of ICC.
|
26255969 |
2015 |
Tauopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
These results demonstrate that decreasing total tau levels is a valid strategy for mitigating tau-related neurodegeneration and reveal Nuak1 to be a novel therapeutic entry point for tauopathies.
|
27720485 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings have highlighted a novel role for NUAK1 in LKB1-related signaling pathways; NUAK1 can regulate cell proliferation and exert tumor suppression through direct interaction with p53.
|
21317932 |
2011 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
These data will lead to investigations of the molecular targets of NUAK1 according to its subcellular distribution, which could be new biomarkers or targets for cancer therapies.
|
31090959 |
2019 |
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
These data will lead to investigations of the molecular targets of NUAK1 according to its subcellular distribution, which could be new biomarkers or targets for cancer therapies.
|
31090959 |
2019 |
Malignant neoplasm of urinary bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, SNHG6 may be a potential prognostic biomarker in BC, and targeting hsa-miR-125b/Snail1/2/NUAK1 axis may be a promising therapeutic approach for BC patients.
|
30168179 |
2019 |
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, SNHG6 may be a potential prognostic biomarker in BC, and targeting hsa-miR-125b/Snail1/2/NUAK1 axis may be a promising therapeutic approach for BC patients.
|
30168179 |
2019 |
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, SNHG6 may be a potential prognostic biomarker in BC, and targeting hsa-miR-125b/Snail1/2/NUAK1 axis may be a promising therapeutic approach for BC patients.
|
30168179 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumorigenicity and spontaneously metastatic capability regulated by ARK5 were determined using an orthotopic xenograft tumor model.
|
22105900 |
2012 |
Nasopharyngeal carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The LINC00958-miR-625-NUAK1 pathway might be a target for anticancer therapy in patients with NPC.
|
31819474 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of NUAK1 was also strongly associated with OS (p = 0.044) and DFS (p = 0.007) in patients of late stage tumour (UICC3-5), but not in patients of early stage tumour (UICC1-2).
|
30121842 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The expression of NUAK1 in primary human NSCLC tissues was evaluated by immunohistochemistry.
|
25412236 |
2014 |
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The elevated ARK5 expression was closely associated with cancer metastasis and patient survival, and it seemed to function in GC cells migration and invasion via EMT alteration, together with the alteration of the mTOR/p70S6k signals, Slug and SIP1, thus providing a potential therapeutic target for GC.
|
28662499 |
2017 |
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The elevated ARK5 expression was closely associated with cancer metastasis and patient survival, and it seemed to function in GC cells migration and invasion via EMT alteration, together with the alteration of the mTOR/p70S6k signals, Slug and SIP1, thus providing a potential therapeutic target for GC.
|
28662499 |
2017 |